Skip to: Curated Story Group 1
lifesciencesreview

Advertise

with us

    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Topics
    Biomanufacturing
    Biomanufacturing
    Biomanufacturing
    Biomanufacturing
    Biomanufacturing
    Business Services
    Business Services
    Business Services
    Business Services
    Business Services
    Drug Discovery
    Drug Discovery
    Drug Discovery
    Drug Discovery
    Drug Discovery
    Pharmacy Management
    Regulatory Services
  • CXO Insights
  • Vendor Viewpoint
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
  • CXO Awards
DECEMBER 2022LIFE SCIENCES REVIEW 19Covaris provides tools and technologies to improve pre-analytical sample preparation, enable novel drug formulations, and manage compounds in the drug discovery process. The Covaris technological foundation is based on its proprietary and patented AFATM technology. AFA enables a vast array of non-contact, isothermal processes to be developed for use in a broad range of applications in Genomics, Proteomics, Cell Biology and Drug Discovery, and FormulationCovariscovaris.comNeoleukin Therapeutics is creating next generation immunotherapies using breakthrough de novo protein design technology. They use natural protein complexes as inspiration to develop custom designed proteins with superior pharmaceutical propertiesNeoleukin Therapeuticsneoleukin.comIntegral Molecular is a research-driven biotechnology company creating innovative technologies and a pipeline of therapeutic antibodies for under-exploited membrane protein targets, including GPCRs, ion channels, and transporters. The Company has over a decade of experience in optimizing membrane proteins, enabling the isolation, characterization, and engineering of monoclonal antibodies against otherwise intractable membrane protein targetsIntegral Molecularintegralmolecular.comPlexium is the premier, next-generation targeted protein degradation company, seeking to discover a wide range of monovalent target protein degraders that address the limitations of PROTACs and cereblon. The company's platform is a proprietary drug discovery platform designed to identify novel small molecules that induce selective degradation of drug target proteins through E3 ligase mediated proteasomal degradationPlexiumplexium.com PROTEOMICS SOLUTIONS COMPANIES - 2022REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adenoassociated virus (AAV) gene therapy. REGENXBIO's NAVĀ® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10REGENXBIOregenxbio.comTOP 10
< Page 9 | Page 11 >